Spinraza

Spinraza is a medication used to treat Spinal muscular atrophy (SMA), a genetic disorder that affects the nerve cells responsible for controlling voluntary muscle movement, as described by Kenneth Fischbeck and Arthur Burghes. It is administered via intrathecal injection, a method also used for Baclofen and Methotrexate, and has been shown to improve motor function in patients with SMA, as demonstrated in studies published in the New England Journal of Medicine and presented at the American Academy of Neurology annual meeting. The development of Spinraza was a collaborative effort between Biogen and Ionis Pharmaceuticals, with significant contributions from researchers at Columbia University and the University of California, Los Angeles.

Introduction

Spinraza, also known as nusinersen, is an antisense oligonucleotide therapy designed to treat SMA, a disease that affects approximately 1 in 10,000 births, according to the National Institutes of Health and the SMA Foundation. The medication works by increasing the production of Survival motor neuron (SMN) protein, which is essential for the survival of motor neurons, as described by Olivier Voinnet and David Corey. Spinraza has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of SMA, and has been shown to be effective in clinical trials conducted at Children's Hospital Boston and the University of Pennsylvania.

Medical_uses

Spinraza is used to treat patients with SMA, including those with Type 1 SMA, Type 2 SMA, and Type 3 SMA, as classified by the World Health Organization and the International Classification of Diseases. The medication has been shown to improve motor function, increase muscle strength, and slow disease progression, as demonstrated in studies published in the Journal of the American Medical Association and presented at the Annual Symposium of the SMA Foundation. Spinraza has also been used to treat patients with SMA who are unable to walk, as well as those who are able to walk but have significant muscle weakness, as described by Richard Finkel and Basil Darras.

Mechanism_of_action

Spinraza works by binding to a specific sequence of Ribonucleic acid (RNA) in the Survival motor neuron 2 (SMN2) gene, which is responsible for producing a truncated and unstable form of the SMN protein, as described by Adrian Krainer and Cold Spring Harbor Laboratory. By binding to this sequence, Spinraza prevents the exclusion of a critical exon from the SMN2 transcript, resulting in the production of a full-length and stable SMN protein, as demonstrated in studies published in the Journal of Biological Chemistry and presented at the Cold Spring Harbor Laboratory meeting. This increase in SMN protein production helps to slow disease progression and improve motor function in patients with SMA, as shown in clinical trials conducted at Duke University and the University of California, San Francisco.

Side_effects

The most common side effects of Spinraza include Respiratory tract infection, Constipation, and Thrombocytopenia, as reported in clinical trials conducted at Johns Hopkins University and the University of Michigan. Other side effects may include Elevated liver enzymes, Nausea, and Vomiting, as described by Robert Darnell and The Rockefeller University. In rare cases, Spinraza may cause more serious side effects, such as Anaphylaxis and Hyponatremia, as reported in the FDA Adverse Event Reporting System and the World Health Organization's VigiBase database.

History

The development of Spinraza began in the early 2000s, when researchers at Ionis Pharmaceuticals and Biogen initiated a collaboration to develop an antisense oligonucleotide therapy for SMA, as described by Stanley Crooke and C. Frank Bennett. The first clinical trials of Spinraza were conducted in 2011, and the medication was approved by the FDA in 2016, following a priority review, as announced by the FDA Commissioner and the National Organization for Rare Disorders. Since its approval, Spinraza has been marketed by Biogen and has become a standard treatment for SMA, with significant contributions from researchers at Harvard University and the University of Oxford.

Pharmacology

Spinraza is administered via intrathecal injection, which involves injecting the medication directly into the spinal canal, as described by Michael Fehlings and the American Association of Neurological Surgeons. The medication is typically administered every 4 months, and the dose is adjusted based on the patient's weight and response to treatment, as recommended by the FDA and the European Medicines Agency. Spinraza is distributed by Biogen and is available in several countries, including the United States, Canada, and European Union member states, as reported by Bloomberg and the Wall Street Journal. Category:Drugs